Social Media Ideas for #Multiplemyeloma

Multiple Myeloma US Leadership

Multiple Myeloma US Leadership Anonymous (not verified) Mon, 07/27/2026 - 18:23 field_thread_url https://cafepharma.com/boards/threads/multiple-myeloma-us-...

emDOCs Podcast – Episode 147: Multiple Myeloma Part 1

Today on the emDOCs cast Brit Long covers part 1 of multiple myeloma: initial presentation and hematologic, renal, and calcium issues. The post emDOCs Podcast – Episode 147: Multip...

All About Myeloma

+ Flipbook textWhat is myeloma? Myeloma is cancer that affects a specific type of white blood cell, called a plasma cell, found in bone marrow. Plasma cells help people fight infec...

Todo sobre el mieloma

English+ Infographic text¿Qué es el mieloma? El mieloma es un cáncer que afecta a un tipo específico de glóbulo blanco, denominado plasmocito, que se encuentra en la médula ósea. L...

Reducing the Multiple Myeloma Mortality Gap

In 2015, Valarie Traynham visited her primary care physician (PCP) after weeks of intense exhaustion, serious nosebleeds, back pain and flu-like infections. Her PCP noted high prot...

Myeloma UK

www.myeloma.org.uk Twitter: @MyelomaUK Primary research areas Blood,  Cancer Additional research areas Generic health relevance Grant types Research Centre, Clinical trial, ...

The New Rule That’s Changing How Doctors Catch the Deadliest Myeloma

A 2026 study redefines functional high-risk multiple myeloma early detection, shifting the relapse benchmark from 18 to 36 months for patients The post The New Rule That’s Changing...

Bristol Myers’ pivotal CAR-T multiple myeloma trial hits primary endpoint

A pivotal trial of Bristol Myers Squibb’s GPRC5D-directed CAR-T cell therapy has hit its primary endpoint, furthering the drugmaker’s efforts to challenge Johnson & Johnson for...

AbbVie’s bispecific T-cell engager shows promise in ph. 3 multiple myeloma trial

AbbVie released positive phase 3 data Thursday showing that its bispecific T-cell engager etentamig improved response rates and progression-free survival in patients with relapsed/...

Mayo Clinic study finds no survival benefit from longer multiple myeloma maintenance therapy

Rochester, Minn. — A major U.S.-led cooperative group clinical trial coordinated by Mayo Clinic researchers has found that extending maintenance therapy with lenalidomide beyond tw...

<![CDATA[FDA Grants Accelerated Approval to Zenbexus Plus Daratumumab and Hyaluronidase-fihj and Dexamethasone for Mu...

Hematogenix's Proprietary MM MRD Assay Underpins FDA Accelerated Approval of Bristol Myers Squibb's ZENBEXUSâ„¢, the Fir...

Hematogenix's proprietary Multiple Myeloma MRD (MM MRD) assay measured the primary efficacy endpoint cited in the FDA-approval of ZENBEXUS (iberdomide), reinforcing Hematogenix's r...

Amyloidosis Continues To Fight Back

Bristol Myers Squibb Protein Degrader Wins First-in-Class FDA Nod in Multiple Myeloma

Bristol Myers Squibb’s Zenbexus is the first FDA-approved drug in a new class of cancer drugs called CELMoDs. The pharma company is positioning this molecule as a successor to its...

Trailing rivals, AbbVie scores win with dual-acting myeloma drug

The drugmaker is leaning on a better side effect profile compared to drugs from J&J, Pfizer and Regeneron as it pushes etentamig toward FDA submission.

Former Mayor of Sligo Veronica Cawley shares myeloma journey to put patients at heart of cancer research

FDA OKs Takeda, Protagonist drug for rare blood cancer

The clearance and broader-than-expected label for Mimrylo open up a yearly revenue opportunity for Takeda that some analysts expect to reach $2 billion or more. 

He Lost His Taste for Beer — It Turned Out to Be Blood Cancer

A man's lost taste for beer led to a multiple myeloma diagnosis. Learn the key symptoms of this incurable blood cancer and when to see a doctor. The post He Lost His Taste for Beer...

Blood Cancer UK

www.bloodcancer.org.uk  Twitter: @bloodcancer_uk  Primary research areas Blood,  Cancer Grant types Clinical trial, Early Career Fellowship, Seed Funding/Pump-priming, Project...

Bristol Myers wins ‘milestone’ FDA approval of myeloma drug acquired from Celgene

The clearance of Zenbexus is the first for a group of protein-degrading “CELMoD” medicines that could help Bristol Myers rejuvenate a key drug franchise.

Leptomeningeal Disease in HER2-Positive Metastatic Breast Cancer

By: Mike Basset From: medpagetoday.com About 110,000 new cases of leptomeningeal disease (metastases of cerebrospinal fluid or the thin membranes that surround the brain and spinal...

Aptevo Reports 93% Clinical Benefit Rate with Mipletamig Triplet in Difficult-to-Treat TP53-Mutated Frontline AML

Remission results nearly double published ven/aza outcomes in patients with historically limited treatment success

When every treatment counts: How clinical trials are changing the outlook for non-Hodgkin lymphoma patients

Discover Andy Brown's long and arduous journey battling a type of non-Hodgkin lymphoma and how a clinical trial altered his treatment outlook. The post When every treatment counts:...

Blood Cancer Therapies Informed by Spatial Remodeling of Bone Marrow

An AI-based approach assesses disease severity in patients with myelodysplastic neoplasms (MDS), a form of blood cancer where one-third of patients progress to a more aggressive st...